Moody Lynn & Lieberson LLC Has $43.98 Million Holdings in AbbVie Inc. $ABBV

Moody Lynn & Lieberson LLC increased its position in AbbVie Inc. (NYSE:ABBV) by 4.9% in the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 192,463 shares of the company’s stock after purchasing an additional 9,001 shares during the period. AbbVie comprises about 2.3% of Moody Lynn & Lieberson LLC’s investment portfolio, making the stock its 13th biggest holding. Moody Lynn & Lieberson LLC’s holdings in AbbVie were worth $43,976,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also modified their holdings of the business. Wellington Management Group LLP lifted its stake in AbbVie by 457.4% in the 3rd quarter. Wellington Management Group LLP now owns 10,536,901 shares of the company’s stock worth $2,439,714,000 after acquiring an additional 8,646,424 shares in the last quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main boosted its holdings in shares of AbbVie by 169.3% during the second quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 4,722,893 shares of the company’s stock worth $876,662,000 after purchasing an additional 2,969,202 shares during the period. Raymond James Financial Inc. boosted its holdings in shares of AbbVie by 41.8% during the second quarter. Raymond James Financial Inc. now owns 9,337,480 shares of the company’s stock worth $1,733,222,000 after purchasing an additional 2,753,312 shares during the period. Amundi grew its position in AbbVie by 36.6% during the second quarter. Amundi now owns 9,093,696 shares of the company’s stock valued at $1,734,623,000 after purchasing an additional 2,435,372 shares in the last quarter. Finally, Alliancebernstein L.P. increased its stake in AbbVie by 31.8% in the 3rd quarter. Alliancebernstein L.P. now owns 7,281,327 shares of the company’s stock valued at $1,685,918,000 after buying an additional 1,758,657 shares during the period. Institutional investors and hedge funds own 70.23% of the company’s stock.

Key Stories Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Earnings momentum and guidance: AbbVie posted a quarterly EPS beat and raised FY‑2026 guidance earlier this year, which supports investor confidence in near‑term earnings and cash flow (background company report).
• Positive Sentiment: Analyst support: BMO (via TipRanks coverage) maintained a Buy rating and $258 price target, reinforcing bullish sentiment among institutional investors. AbbVie: Immunology Strength, Strategic Acquisitions, and Patent Headwind Execution Support Buy Rating
• Positive Sentiment: Institutional buying: Beacon Investment Advisory increased its stake in ABBV, signaling continued institutional interest. Beacon Investment Advisory Services Inc. Has $19.86 Million Stock Position in AbbVie Inc. $ABBV
• Positive Sentiment: Aesthetics business activity: Allergan Aesthetics (an AbbVie unit) launched promotional CoolMonth offers and presented safety/efficacy data at AAD — both support the aesthetics revenue story. Allergan Aesthetics Announces Fourth Annual, All-Access CoolMonth with Deals on CoolSculpting® Allergan Aesthetics Releases Findings on the Safety and Efficacy of Repeat TrenibotE Treatments and Data on Medical Weight Loss Aesthetics Patient Behaviors at the 2026 AAD
• Positive Sentiment: Macro tax tailwind: Analysis shows corporate cash taxes fell materially under the new tax law, a factor that can boost free cash flow for large pharma including AbbVie. US Corporate Taxes Drop $65 Billion After Trump’s $3.4 Trillion Tax Law
• Neutral Sentiment: Stock commentary: MarketWatch notes ABBV rose but still slightly underperformed the broader market on the day; useful context for relative performance. AbbVie Inc. stock rises Tuesday, still underperforms market
• Neutral Sentiment: Upcoming event: AbbVie set its Q1 2026 earnings release and conference call for April 29 — an event that could drive volatility and provide fresh guidance. AbbVie to Host First-Quarter 2026 Earnings Conference Call
• Neutral Sentiment: Competitive messaging: AbbVie publicly defends Skyrizi’s efficacy edge as J&J launches Icotyde — shows competitive dynamics in immunology/dermatology but not an immediate structural change. As J&J Brings Icotyde to Market, AbbVie Remains Confident in Skyrizi’s Efficacy Edge
• Negative Sentiment: Oncology pressure: Analyst coverage (Zacks) highlights 2026 headwinds for AbbVie’s oncology revenue — Imbruvica pricing pressure may weigh on top‑line growth despite newer drug contributions. Will AbbVie’s Oncology Drugs Aid Top Line in 2026?
• Negative Sentiment: Lawsuit tied to Cerevel deal: A Bloomberg Law item says investors’ suit over the Cerevel deal involving Pfizer/Bain must proceed, which could raise legal risk/uncertainty around the transaction and reputational exposure. Pfizer, Bain Must Litigate Cerevel Investors’ AbbVie Deal Suit
• Negative Sentiment: Peer M&A strengthens competition: Merck’s large oncology deal (Terns) reinforces competitive pressure in oncology — a potential headwind for AbbVie’s oncology growth narrative. Merck Just Made a Big Bet on a New Cancer Growth Engine

Insider Activity at AbbVie

In other news, EVP Perry C. Siatis sold 22,381 shares of the stock in a transaction that occurred on Wednesday, February 25th. The stock was sold at an average price of $230.00, for a total value of $5,147,630.00. Following the completion of the sale, the executive vice president directly owned 38,137 shares of the company’s stock, valued at approximately $8,771,510. This represents a 36.98% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP David Ryan Purdue sold 5,230 shares of the firm’s stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $233.56, for a total transaction of $1,221,518.80. Following the completion of the sale, the senior vice president owned 2,654 shares in the company, valued at approximately $619,868.24. The trade was a 66.34% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 0.08% of the company’s stock.

AbbVie Trading Up 2.0%

NYSE:ABBV opened at $217.39 on Wednesday. The firm has a market capitalization of $384.38 billion, a PE ratio of 92.11, a PEG ratio of 0.74 and a beta of 0.34. AbbVie Inc. has a 1 year low of $164.39 and a 1 year high of $244.81. The firm’s fifty day simple moving average is $222.00 and its 200 day simple moving average is $224.65.

AbbVie (NYSE:ABBV) last released its earnings results on Wednesday, February 4th. The company reported $2.71 earnings per share for the quarter, topping analysts’ consensus estimates of $2.65 by $0.06. The firm had revenue of $16.62 billion during the quarter, compared to analyst estimates of $16.39 billion. AbbVie had a net margin of 6.91% and a negative return on equity of 1,579.75%. The business’s revenue was up 10.0% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.16 EPS. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. As a group, analysts anticipate that AbbVie Inc. will post 12.31 EPS for the current fiscal year.

AbbVie Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Wednesday, April 15th will be paid a dividend of $1.73 per share. The ex-dividend date is Wednesday, April 15th. This represents a $6.92 annualized dividend and a yield of 3.2%. AbbVie’s dividend payout ratio is presently 293.22%.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on the stock. Weiss Ratings reissued a “hold (c)” rating on shares of AbbVie in a research note on Wednesday, January 21st. HSBC upgraded AbbVie from a “hold” rating to a “buy” rating and increased their price objective for the stock from $225.00 to $265.00 in a report on Wednesday, December 10th. Evercore reduced their price objective on AbbVie from $232.00 to $228.00 and set an “outperform” rating for the company in a research report on Wednesday, February 4th. Berenberg Bank set a $275.00 target price on AbbVie in a research report on Tuesday, January 20th. Finally, Piper Sandler raised their price target on AbbVie from $289.00 to $299.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 18th. Two research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $253.15.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.